Angelo Cardoso, M.D., Ph.D. brings two decades of international, groundbreaking leukemia research to his new role at the Center for Gene Therapy.
Dr. Cardoso was educated in Portugal, where he received his medical degree. He earned his Ph.D. from the University of Paris, after completing doctoral research work in France, Portugal, and here in the U.S. at Harvard's Dana-Farber Cancer Institute. He spent a decade at Harvard Medical School and Dana-Farber Cancer Institute as an Instructor of Medicine, then taught medicine and molecular genetics at Indiana University School of Medicine.
Dr. Cardoso focuses on the genetic mechanism of leukemia, especially acute lymphoblastic leukemia (ALL) in children.
At the Center for Gene Therapy, Dr. Cardoso will examine, in his words, “molecular crosstalk between leukemia cells and the bone marrow microenvironment,” as the disease progresses. One of his goals will be to develop “selective inhibitors for high-risk and refractory, relapsed pediatric ALL.”
Molecular crosstalk between leukemia cells and the bone marrow (BM) microenvironment, and how oncogenic signals are integrated with microenvironmental cues during leukemogenesis and leukemia progression. Role of the IL-7/Notch/PI3K axis and of IL-7/STAT3 signaling in ALL biology and disease relapse. Ref-1/APE1 and redox control of leukemia-associated transcriptional programs (STAT3, NF-kB, …) in the regulation of pro-survival and cell cycle in pediatric ALL. Target identification and validation, and pre-clinical development of selective inhibitors for high-risk and refractory, relapsed pediatric ALL; drug development and studies to define pharmacological profile of novel molecular inhibitors. Impact of tumor-stimulated endothelium on leukemia cell biology and regulation of leukemia-initiating cells; role of TGF-β/TWEAK-R/NF-κB signaling in tumor angiogenesis and endothelial/leukemia crosstalk. Intravital microscopy to define endothelial niches supporting leukemia, and to monitor targeted therapy responses in models of high-risk, relapse ALL.
Zhang H, Rodriguez S, Wang L, Wang S, Serezani H, Kapur R, Cardoso AA and Carlesso N. Differential contribution of TRIF and MyD88 in regulating TLR4 induced exhaustion of hematopoietic stem and progenitor cells during sepsis. Stem Cell Reports 2016 (accepted for publication). ;
Wang L, Rodriguez S, Zhang H, Cao L, Parish J, Mumaw C, Zollman A, Kamoka M, Mu J, Chen DZ, Srour E, Chitteti B, Hoegenesh H, Boswell S, Manshouri T, Verstovsek S, Yoder M, Kapur R, Cardoso AA, Carlesso N. Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in a NF-κB dependent manner. Cell Stem Cell 2014; 15: 51-65. ;
Chitteti BR, Kobayashi M, Cheng Y, Hu P, Zhang H, Poteat BA, Broxmeyer HE, Pelus LM, Hanenberg H., Zollman A, Kamocka G, Carlesso N, Cardoso AA, Kacena M, Srour EF. CD166 regulates human and murine hematopoietic stem cells and the hematopoietic niche. Blood 2014; 124: 519-529. ;
Yoshimoto M, Porayette P, Glosson NL, Conway SJ, Carlesso N, Cardoso AA, Kaplan MH, Yoder MC. Autonomous murine T-cell progenitor production in the extra-embryonic yolk sac before HSC emergence. Blood 2012; 119: 5706-5714. ;
Cardoso AA, Jiang Y, Luo M, Reed AM, He Y, Kelley MR, Fishel ML. APE1/Ref-1 Redox Function regulates STAT3 transcriptional activity and Ref-1/STAT3 dual-targeting synergize to effectively inhibit pancreatic cancer cell survival. PLoS ONE 2012; 7: e47462. ;
Gökmen-Polar Y, Sanders KL, Goswami C, Cano OD, Zaheer NA, Jain RK, Kessler KA, Nelson Jr RP, Vance GH, Smith D, Li L, Cardoso AA, Badve S, Loehrer Sr PJ, Sledge Jr GW. Establishment and characterization of a novel cell line derived from human thymoma A/B tumor. Lab Inv 2012; 92:1564-73. ;
Yoshimoto M, Porayette P, Glosson NL, Conway SJ, Carlesso N, Cardoso AA, Kaplan MH, Yoder MC. Autonomous T cell progenitor production in the extra-embryonic yolk sac prior to HSC emergence. Blood 2012; 119: 5706-5714. ;
Shanmugam R, Gade P, Wilson-Weekes A, Sayar H, Suvannasankha A, Goswami C, Li, Cardoso AA, Al Baghdadi T, Sargent KJ, Cripe LD, Kalvakolanu DV, Boswell HS. A non-canonical Flt3ITD/NF-κB signaling pathway represses DAPK1 in acute myeloid leukemia. Clin Cancer Res 2012; 18: 360-369. ;
Maia S, Pelletier M, Ding J, Hsu YM, Sallan SE, Nadler LM, Rao SP, Cardoso AA. Aberrant expression of functional BAFF-system receptors in malignant B-cell precursors impacts leukemia cell survival. PLoS ONE 2011; 6: e20787. ;
Batista A, Barata JT, Raderschall E, Sallan SE, Carlesso N, Nadler LM, Cardoso AA. Targeting of active mTOR inhibits primary leukemia T-cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol 2011; 39:457-472. ;
Vasconcellos JF, Laranjeira AB, Zanchin N, Otubo R, Vaz TH, Cardoso AA., Brandalise SR, Yunes JA. Increased CCL2 and IL-8 in the malignant bone marrow microenvironment in acute lymphoblastic leukemia. Pediat Blood Cancer 2011; 56:568-575. ;
Balcells M, Martorell J, Olive C, Santacana M, Chitalia V, Cardoso AA, Edelman ER. Smooth muscle cells orchestrate the endothelial cell response to flow and injury. Circulation 2010; 121: 2192-2199. ;
Cardoso B, Martins LR, Santos C, Nadler LM, Boussiotis VA, Cardoso AA, Barata JT. Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling. Leukemia 2009; 23: 206-208. ;
Yunes JA, Cardoso AA, Yunes RA, Correa R, Campos-Buzzi F, Cechinel-Filho V. Antiproliferative effects of a series of cyclic imides on primary endothelial cells and a leukemia cell line. Z. Naturforsch. 2008; 63: 675-680.